| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | CTLA-4, CTLA4, CD152-muIg, CTLA-4-Ig |
| Conjugate | |
| Formulation | |
| Host | |
| Product Type | |
| Shipping | |
| Storage |
Scientific Background
Human CD152 (CTLA-4) is a cell surface glycoprotein expressed at low levels on activated T cells (1). CD152 is a high affinity receptor for the costimulatory molecules CD80 (B7-1) and CD86 (B7-2) and appears to function as a negative regulator of T cell activation (2, 3). A soluble fusion protein combining the extracellular (125aa) domain of human CD152 and murine IgG2a Fc (CTLA-4 Ig) was developed (4).
Product Description
Mammalian (BHK)Recombinant hCD152(CTLA-4)-muIg is a recombinant human fusion protein produced in Mammalian (BHK) cells. Molecular Structure: A soluble 110 kd dimeric fusion protein consisting of the extracellular (125aa) domain of human CTLA-4 fused to murine IgG2a Fc (233aa), with a predicted non glycosylated monomeric molecular weight of 40.1 kd.
Alternative names: CTLA-4, CTLA4, CD152-muIg, CTLA-4-Ig
Protein Specifications
| Fusion Format | Murine IgG Fc Fusion (muIg) |
|---|---|
| Expression System | Mammalian (BHK) |
| Molecular Weight | 110 kDa |
| Formulation | 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5% Gentamicin sulfate |
| Storage | Store at 2 - 5°C. Freeze/Thawing is not recommended. |
| Species Reactivity | Human, Primate, Mouse, Pig, Cow, Cat |
| Validated Applications | ELISA, Flow Cytometry |
| Available Conjugates | APC, Biotin, FITC, PE, Unconjugated |
✔ Research Use Only (RUO)
Functional Activity
CD152 Ig binds with high affinity to human or mouse CD80 (B7-1) and CD86 (B7-2) (4, 5). CD152-muIg blocks the binding of anti-human CD80 (B7-1) and anti-humanCD86 (B7-2) mAbs to recepters on Raji cells. It cross reacts with CD80 and CD86 accross a broad range of mammalian species including pig (6, 7).
Safety & Handling
Research Use Only. Not intended for diagnostic, therapeutic, or clinical use. Handle according to good laboratory practice (GLP). Consult the Safety Data Sheet (SDS) prior to use.
Related Products
Browse our full collection of recombinant proteins and antibodies for immunology and immune checkpoint research.
This protein was expressed in Mammalian (BHK) cells. Mammalian expression is critical for this Fc fusion protein because it ensures proper glycosylation and tertiary folding of the extracellular immunoglobulin-like domains, preserving native receptor-binding activity.
Recombinant hCD152(CTLA-4)-muIg has been validated for: ELISA, Flow Cytometry. It is produced as a Murine IgG Fc Fusion (muIg), making it suitable as a blocking reagent, binding standard, or functional stimulant/inhibitor in immunology assays.
Recommended storage: Store at 2 - 5°C. Freeze/Thawing is not recommended.. Formulation: 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5% Gentamicin sulfate. Avoid repeated freeze-thaw cycles. If long-term storage is needed, aliquot upon first use.
Species reactivity includes: human, primate, mouse, pig, cow, cat. Cross-reactivity was confirmed by functional binding assays (e.g., ELISA and/or FACS) against cells or recombinant proteins from the indicated species.
Available formats include: APC, Biotin, FITC, PE, Unconjugated. Conjugated forms are ready-to-use without secondary detection reagents for flow cytometry. Unconjugated (purified) forms can be used with anti-Fc secondary antibodies in ELISA.
Can't Find What You're Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- T. Lindsten, et al, (1993) J Immunol 151: 3489-3499.
- T.L. Walunas, et al, (1994) Immunity 1: 405-413.
- N.J. Karandikar, et al, (1996) J Exp Med 184: 783-788.
- A.H. Cross, et al, (1995) J Clin Invest 95: 2783-2789.
- P.A. Morton, et al, (1996) J Immunol 156: 1047-1054.
- Takamatsu H, RME Parkhouse, et al. (1999) Immunology 97(2):211-213.
- Le Leduec JB, B Dubois, et al. (2016) Vaccine 34(7): 914-22. PMID: 26768129
